Literature DB >> 20389023

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Davide Corti1, Amorsolo L Suguitan, Debora Pinna, Chiara Silacci, Blanca M Fernandez-Rodriguez, Fabrizia Vanzetta, Celia Santos, Catherine J Luke, Fernando J Torres-Velez, Nigel J Temperton, Robin A Weiss, Federica Sallusto, Kanta Subbarao, Antonio Lanzavecchia.   

Abstract

The target of neutralizing antibodies that protect against influenza virus infection is the viral protein HA. Genetic and antigenic variation in HA has been used to classify influenza viruses into subtypes (H1-H16). The neutralizing antibody response to influenza virus is thought to be specific for a few antigenically related isolates within a given subtype. However, while heterosubtypic antibodies capable of neutralizing multiple influenza virus subtypes have been recently isolated from phage display libraries, it is not known whether such antibodies are produced in the course of an immune response to influenza virus infection or vaccine. Here we report that, following vaccination with seasonal influenza vaccine containing H1 and H3 influenza virus subtypes, some individuals produce antibodies that cross-react with H5 HA. By immortalizing IgG-expressing B cells from 4 individuals, we isolated 20 heterosubtypic mAbs that bound and neutralized viruses belonging to several HA subtypes (H1, H2, H5, H6, and H9), including the pandemic A/California/07/09 H1N1 isolate. The mAbs used different VH genes and carried a high frequency of somatic mutations. With the exception of a mAb that bound to the HA globular head, all heterosubtypic mAbs bound to acid-sensitive epitopes in the HA stem region. Four mAbs were evaluated in vivo and protected mice from challenge with influenza viruses representative of different subtypes. These findings reveal that seasonal influenza vaccination can induce polyclonal heterosubtypic neutralizing antibodies that cross-react with the swine-origin pandemic H1N1 influenza virus and with the highly pathogenic H5N1 virus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20389023      PMCID: PMC2860935          DOI: 10.1172/JCI41902

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Mark Eid; Darya Zharikova; Walter Gerhard
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

Review 2.  Evolution and ecology of influenza A viruses.

Authors:  R G Webster; W J Bean; O T Gorman; T M Chambers; Y Kawaoka
Journal:  Microbiol Rev       Date:  1992-03

3.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

4.  Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number.

Authors:  E H Sasso; T Johnson; T J Kipps
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

5.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

Authors:  A J Caton; G G Brownlee; J W Yewdell; W Gerhard
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

6.  Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Authors:  T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls.

Authors:  Ron A M Fouchier; Vincent Munster; Anders Wallensten; Theo M Bestebroer; Sander Herfst; Derek Smith; Guus F Rimmelzwaan; Björn Olsen; Albert D M E Osterhaus
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera.

Authors:  M L Wang; J J Skehel; D C Wiley
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

9.  Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains.

Authors:  Y Okuno; K Matsumoto; Y Isegawa; S Ueda
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

Review 10.  Variation and infectivity neutralization in influenza.

Authors:  Marcel Knossow; John J Skehel
Journal:  Immunology       Date:  2006-09       Impact factor: 7.397

View more
  255 in total

1.  Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.

Authors:  Yao-Qing Chen; Linda Yu-Ling Lan; Min Huang; Carole Henry; Patrick C Wilson
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

3.  Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.

Authors:  Yuan Fang; David Banner; Alyson A Kelvin; Stephen S H Huang; Christopher J Paige; Steven A Corfe; Kevin P Kane; R Chris Bleackley; Thomas Rowe; Alberto J Leon; David J Kelvin
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

4.  Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation.

Authors:  Jacob Glanville; Tracy C Kuo; H-Christian von Büdingen; Lin Guey; Jan Berka; Purnima D Sundar; Gabriella Huerta; Gautam R Mehta; Jorge R Oksenberg; Stephen L Hauser; David R Cox; Arvind Rajpal; Jaume Pons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

5.  Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion.

Authors:  Shin Murakami; Taisuke Horimoto; Mutsumi Ito; Ryo Takano; Hiroaki Katsura; Masayuki Shimojima; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

Review 6.  Aging, cytomegalovirus (CMV) and influenza vaccine responses.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

7.  Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9.

Authors:  Cong Chen; Liguo Liu; Yan Xiao; Sheng Cui; Jianmin Wang; Qi Jin
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

Review 8.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

9.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

Review 10.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.